Richard Beckman - Sep 19, 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Medical Officer
Signature
Richard Beckman by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Sep 19, 2022
Transactions value $
-$4,570
Form type
4
Date filed
9/21/2022, 08:01 PM
Previous filing
Sep 21, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Sale -$4.57K -4.27K -9.86% $1.07 39.1K Sep 19, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
F2 The reporting person's sale of Adverum common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's purchase of the same number of shares of Adverum common stock at a price of $0.8228 per share on May 17, 2022. The reporting person has paid to Adverum $1,055.01, representing the full amount of the profit realized in connection with the short-swing transaction.
F3 Price reported is a weighted-average sale price. The shares were sold at prices ranging from $1.069589 to $1.0721. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.